TuHURA Biosciences (NASDAQ:HURA) Announces Earnings Results, Beats Estimates By $0.02 EPS

TuHURA Biosciences (NASDAQ:HURA) issued its quarterly earnings data on Tuesday. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02, FiscalAI reports.

TuHURA Biosciences Price Performance

NASDAQ:HURA traded up $0.06 during mid-day trading on Tuesday, reaching $1.79. The stock had a trading volume of 265,409 shares, compared to its average volume of 806,305. The company has a market capitalization of $108.69 million, a price-to-earnings ratio of -3.58 and a beta of -0.30. TuHURA Biosciences has a 1-year low of $0.41 and a 1-year high of $4.44. The stock’s 50 day simple moving average is $1.34 and its two-hundred day simple moving average is $1.64.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in shares of TuHURA Biosciences during the third quarter worth $26,000. JPMorgan Chase & Co. acquired a new position in shares of TuHURA Biosciences in the 2nd quarter valued at about $27,000. Invesco Ltd. bought a new stake in shares of TuHURA Biosciences during the 2nd quarter valued at about $30,000. State Street Corp raised its stake in TuHURA Biosciences by 4.9% during the fourth quarter. State Street Corp now owns 289,133 shares of the company’s stock worth $219,000 after acquiring an additional 13,594 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in TuHURA Biosciences during the second quarter worth about $31,000. Institutional investors own 0.62% of the company’s stock.

Analyst Upgrades and Downgrades

HURA has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of TuHURA Biosciences in a research report on Tuesday, February 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of TuHURA Biosciences from a “sell” rating to a “hold” rating in a research note on Monday. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $9.00.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.